Trial · NCT07908498
Non-invasive Vagus Nerve Stimulation for Parkinson's Disease
NCT07908498, Not applicable, Not yet recruiting, Chinese University of Hong Kong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Non-invasive Vagus Nerve Stimulation for Parkinson's Disease. Trials, record NCT07908498. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908498
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Non-invasive Vagus Nerve Stimulation for Parkinson's Disease
- NCT number
- NCT07908498
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Chinese University of Hong Kong
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- cVNS, eVNS, sVNS
- First posted
- 2026-11-02
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of gait | Baseline, Day 1 stimulation visit, 4 week post-home stimulation visits and 8 week post-home stimulation visits | Timed UP and Go test: Participant sits back in a standard armchair with their back against the chair and hands resting on the armrests. Regular footwear and usual walking aids (like a cane or walker) are used. On the word "Go", the person stands up, walks a distance of 3 meters (10 feet) to a marked line or cone at a normal, safe pace, turns around, walks back to the chair, and sits down again. A stopwatch starts the moment the word "Go" is spoken and stops the moment the person's buttocks touch the seat. The results in second will be interpret to assist mobility and risk of falling. The longer the time, the high risk of fall |
| Primary | Severity and progression of Parkinson's disease | Baseline, Day 1 stimulation visit, 4 week post-home stimulation visits and 8 week post-home stimulation visits | Using Unified Parkinson's Disease Rating Scale to motor and non-motor symptoms. Score from 0 to 4. 0 is normal while 4 is severe/marked impairment |
| Primary | Quantitative Gait Assessment | Baseline, Day 1 stimulation visit, 4 week post-home stimulation visits and 8 week post-home stimulation visits | Using an app to track the mobility of participants in a 20 sec walking |
| Primary | Cognitive status | Baseline, Day 1 stimulation visit, 4 week post-home stimulation visits and 8 week post-home stimulation visits | Using Hong Kong Montreal Cognitive Assessment to evaluate the cognitive status. score from 0-30. The lower the score, the more cognitive impaired. |
| Primary | Change in mood | Baseline, Day 1 stimulation visit, 4 week post-home stimulation visits and 8 week post-home stimulation visits | Using Geriatric depression scale which contain 15 questions. Score from 0-15. The higher the score, the more severe the depressed mood |
| Secondary | Change of blood pressure | Baseline, Day 1 stimulation visit, 4 week post-home stimulation visits and 8 week post-home stimulation visits | |
| Secondary | Safety measures- record of adverse event and serious adverse event | Baseline, Day 1 stimulation visit, 4 week post-home stimulation visits and 8 week post-home stimulation visits | To investigate any possibility and relativity of AE and SAE with the treatment |
| Secondary | Electrocardiogram | Baseline, Day 1 stimulation visit, 4 week post-home stimulation visits and 8 week post-home stimulation visits | To investigate any possibility and relativity of the change of ECG with the treatment |
| Other | Blood-based biomarkers | Baseline, Day 1 stimulation visit, 4 week post-home stimulation visits and 8 week post-home stimulation visits |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908498
GET https://conductscience.org/api/trials/v1/NCT07908498/registered